Search

everythinglearnresearchcommunity

for

Search:↓

Androgenetic alopecia is common, affects self-image, and has no complete cure yet.

Mutations in the AR gene cause hair thinning and loss.

The BJUI supports clinical trials as key for unbiased medical evidence and works to enhance their design, reporting, and discussion.

Alopecia should be treated as a medical condition because it may increase the risk of serious diseases and psychological issues.

The structure of SRD5A reveals how it reduces steroids, aiding drug design for related health conditions.

5α-reductase is essential for male sexual development and its inhibitors have potential in treating various conditions related to hormone action.

Antiandrogens affect androgen-dependent body functions and are used for various medical conditions, with some risks like fetus feminization, but new forms like 17α-propylmesterolone show promise for acne without systemic effects.

New sulfur-containing steroid analogs show promise for more targeted medical treatments.

COVID-19 might worsen symptoms and progression of benign prostatic hyperplasia, possibly due to inflammation and metabolic disturbances in the prostate gland. More research is needed to confirm this.

Combining flutamide and finasteride can reduce prostate weight and tumor growth, potentially benefiting treatments needing optimal DHT inhibition.

Large prostates link to more hair loss.

PSA levels could help detect illegal steroid use in female athletes but face challenges like cost and PCOS prevalence.

The document concludes that targeting the androgen receptor may be a promising breast cancer treatment, especially for certain types.

The activity of a specific rat enzyme in the prostate and epididymis is highly dependent on the acidity level.

Finasteride use may increase the risk of male breast cancer.

Women with alopecia may have a higher chance of getting thyroid cancer.

New steroids were effective in blocking male hormone receptors in hamster prostates.

Sex hormones might influence bladder cancer development, and aromatase inhibitors could increase risk in postmenopausal women.

Flutamide and a new synthetic steroid affected brain and prostate chemicals and showed potential for treating androgen-related conditions and epilepsy.

Vertex baldness has higher DHT levels than frontal baldness, but testosterone and PSA levels are similar.

PSA could be a marker for hyperandrogenism in women, but more research is needed.

PSA might help diagnose PCOS and related skin issues, but more research is needed.

Targeting colon cancer stem cells might lead to better treatment results.

Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.

Older adults have a high rate of skin cancers like basal cell carcinoma and melanoma, mainly due to UV exposure and age.

Dutasteride and finasteride do not significantly affect bone density, blood fats, or blood production, but slightly lower PSA levels and minimally impact sexual function in healthy young men.

Male cancer patients have a higher risk of severe illness and death from COVID-19 than female patients.

The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.

Men taking 5-alpha-reductase inhibitors before or after bladder cancer diagnosis had a lower risk of dying from the disease.

Men with male pattern baldness have a higher risk of certain skin cancers, especially on the scalp.